Literature DB >> 25756299

Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.

Jessica A Hall1, Sahithi Seedarala1, Nichole Rice, Lucas Kopel, Fathi Halaweish, Brian S J Blagg1.   

Abstract

Heat shock protein 90 (Hsp90) facilitates the maturation of many newly synthesized and unfolded proteins (clients) via the Hsp90 chaperone cycle, in which Hsp90 forms a heteroprotein complex and relies upon cochaperones, immunophilins, etc., for assistance in client folding. Hsp90 inhibition has emerged as a strategy for anticancer therapies due to the involvement of clients in many oncogenic pathways. Inhibition of chaperone function results in client ubiquitinylation and degradation via the proteasome, ultimately leading to tumor digression. Small molecule inhibitors perturb ATPase activity at the N-terminus and include derivatives of the natural product geldanamycin. However, N-terminal inhibition also leads to induction of the pro-survival heat shock response (HSR), in which displacement of the Hsp90-bound transcription factor, heat shock factor-1, translocates to the nucleus and induces transcription of heat shock proteins, including Hsp90. An alternative strategy for Hsp90 inhibition is disruption of the Hsp90 heteroprotein complex. Disruption of the Hsp90 heteroprotein complex is an effective strategy to prevent client maturation without induction of the HSR. Cucurbitacin D, isolated from Cucurbita texana, and 3-epi-isocucurbitacin D prevented client maturation without induction of the HSR. Cucurbitacin D also disrupted interactions between Hsp90 and two cochaperones, Cdc37 and p23.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25756299      PMCID: PMC5892428          DOI: 10.1021/acs.jnatprod.5b00054

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  49 in total

1.  Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells.

Authors:  H R Kim; H S Kang; H D Kim
Journal:  IUBMB Life       Date:  1999-10       Impact factor: 3.885

Review 2.  Hsp90 as a target for drug development.

Authors:  Subhabrata Chaudhury; Timothy R Welch; Brian S J Blagg
Journal:  ChemMedChem       Date:  2006-12       Impact factor: 3.466

3.  Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol.

Authors:  Sridhar Sreeramulu; Santosh Lakshmi Gande; Michael Göbel; Harald Schwalbe
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

Review 4.  Cucurbitacins as inducers of cell death and a rich source of potential anticancer compounds.

Authors:  J L Ríos; I Andújar; J M Escandell; R M Giner; M C Recio
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  1H and 13C NMR signal assignment of cucurbitacin derivatives from Citrullus colocynthis (L.) Schrader and Ecballium elaterium L. (Cucurbitaceae).

Authors:  Christoph Seger; Sonja Sturm; Maria-Elisabeth Mair; Ernst P Ellmerer; Hermann Stuppner
Journal:  Magn Reson Chem       Date:  2005-06       Impact factor: 2.447

Review 6.  Cucurbitacin: ancient compound shedding new light on cancer treatment.

Authors:  Dhong Hyun Lee; Gabriela B Iwanski; Nils H Thoennissen
Journal:  ScientificWorldJournal       Date:  2010-03-05

7.  Geldanamycin restores a defective heat shock response in vivo.

Authors:  K F Winklhofer; A Reintjes; M C Hoener; R Voellmy; J Tatzelt
Journal:  J Biol Chem       Date:  2001-09-26       Impact factor: 5.157

8.  Direct Aerobic α, β-Dehydrogenation of Aldehydes and Ketones with a Pd(TFA)(2)/4,5-Diazafluorenone Catalyst().

Authors:  Tianning Diao; Tyler J Wadzinski; Shannon S Stahl
Journal:  Chem Sci       Date:  2011-10-31       Impact factor: 9.825

9.  Chemical studies on Mexican plants used in traditional medicine, V. Cucurbitacin glucosides from Cigarrilla mexicana.

Authors:  R Mata; P Castañeda; M Camacho; G Delgado
Journal:  J Nat Prod       Date:  1988 Sep-Oct       Impact factor: 4.050

10.  Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.

Authors:  Eloisi Caldas-Lopes; Leandro Cerchietti; James H Ahn; Cristina C Clement; Ana I Robles; Anna Rodina; Kamalika Moulick; Tony Taldone; Alexander Gozman; Yunke Guo; Nian Wu; Elisa de Stanchina; Julie White; Steven S Gross; Yuliang Ma; Lyuba Varticovski; Ari Melnick; Gabriela Chiosis
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-05       Impact factor: 11.205

View more
  7 in total

1.  Asymmetric De Novo Synthesis of a Cucurbitane Triterpenoid: Total Synthesis of Octanorcucurbitacin B.

Authors:  Andrea R Bucknam; Glenn C Micalizio
Journal:  J Am Chem Soc       Date:  2022-05-09       Impact factor: 16.383

2.  Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer.

Authors:  Mohammed Sikander; Bilal Bin Hafeez; Shabnam Malik; Abdulrhman Alsayari; Fathi T Halaweish; Murali M Yallapu; Subhash C Chauhan; Meena Jaggi
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

3.  Cucurbitacin D impedes gastric cancer cell survival via activation of the iNOS/NO and inhibition of the Akt signalling pathway.

Authors:  Yan Zhen Zhang; Chun Feng Wang; Lian Feng Zhang
Journal:  Oncol Rep       Date:  2018-04-10       Impact factor: 3.906

Review 4.  Targeting Chaperone/Co-Chaperone Interactions with Small Molecules: A Novel Approach to Tackle Neurodegenerative Diseases.

Authors:  Lisha Wang; Liza Bergkvist; Rajnish Kumar; Bengt Winblad; Pavel F Pavlov
Journal:  Cells       Date:  2021-09-29       Impact factor: 6.600

Review 5.  Inhibitors of the Plasmodium falciparum Hsp90 towards Selective Antimalarial Drug Design: The Past, Present and Future.

Authors:  Melissa Louise Stofberg; Celine Caillet; Marianne de Villiers; Tawanda Zininga
Journal:  Cells       Date:  2021-10-22       Impact factor: 6.600

Review 6.  The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition.

Authors:  Michael A Serwetnyk; Brian S J Blagg
Journal:  Acta Pharm Sin B       Date:  2020-11-24       Impact factor: 11.413

7.  Novel Mechanistic Insight into the Anticancer Activity of Cucurbitacin D against Pancreatic Cancer (Cuc D Attenuates Pancreatic Cancer).

Authors:  Mohammed Sikander; Shabnam Malik; Sheema Khan; Sonam Kumari; Neeraj Chauhan; Parvez Khan; Fathi T Halaweish; Bhavin Chauhan; Murali M Yallapu; Meena Jaggi; Subhash C Chauhan
Journal:  Cells       Date:  2019-12-31       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.